Medifast Is Worth Less Than Its Cash — And It Just Quietly Retired the Word 'Stabilization'
Q3 revenue fell 19% to $72 million, Q4 guidance implies another big step down, and the metric management calls 'coach productivity' is mostly coach attrition wearing a suit.
MED · Earnings Call · 2026-10-26
The market is paying negative for the business
Medifast ended the third quarter with $72 million of revenue, $172.5 million in cash and investments, and no debt. Its market capitalization is roughly $135 million. That means the entire operating company — the Trilogy brand, the coach network, the MetaVantage ingredient platform, the Metabolic Health Institute — is being valued at something like negative $37 million by the public market.
Nick Johnson, in his first call as CEO, put it plainly:
We ended the quarter with $173 million in cash and investments and no debt. And our enterprise value continues to sit below the value of our cash and investments.
It is a remarkable thing to say out loud, and more remarkable that no one asked about it. The Q&A ran three questions, all from the same Stephens analyst. There was no question about buybacks — and the buyback line, repurchase of common stock, has been zero for years. Instead, the closest thing to a capital-return signal came from an unusual place: field leaders putting their own money in.
“They are choosing to invest their time in leadership, as well as their own capital through ownership in the company.” — Nicholas Johnson, Chief Executive Officer · 2026-10-26
That is a new generation of leaders story, and it is the single most under-examined item on the call. No terms, no size, no structure was disclosed. Either it is a private placement that matters, or it is color. Management left it as color.
Stabilization, retired in one clause
In prepared remarks, Johnson said the company delivered “revenue in line with guidance at $72 million. Continuing the trend of stabilizing revenue around $75 million for the fourth consecutive quarter.” — Nicholas Johnson, Chief Executive Officer · 2026-10-26 Two minutes later, CFO James Maloney guided Q4 to $55–75 million. Take the midpoint of $65 million and the "stabilization" framing is gone: that is a double-digit sequential decline off a quarter that was itself down from $76 million in Q2.
At the same time, the coach count keeps falling. Active earning coaches were approximately 10.2 thousand versus 19.5 thousand a year ago, and the guide is explicit: “the total number of active earning coaches remains below last year's level. And we expect that trend to continue in the near term.” — Nicholas Johnson, Chief Executive Officer · 2026-10-26 The coach count keyword is now a steady feature of these calls — not because it is growing, but because it is the thing that keeps not growing.
This is where the prior record bites. In November 2025, Maloney set a timetable: “we're anticipating that to happen in Q4, but at a minimum, getting back to revenue per active earning coach growth, we believe, will happen at least in the next 6 months.” — James Maloney, Chief Financial Officer · 2025-11-03 In May 2026, Johnson framed the sequence as mechanical: “Productivity tends to be that leading indicator in our business.” — Nicholas M. Johnson, President · 2026-05-04 Four quarters of "leading indicator" later, the lagging variable it is supposed to lead is still declining, and the company is now guiding revenue down sequentially again.
Productivity is arithmetic before it is execution
The headline number is genuinely striking: revenue per active earning coach of $7.06 thousand, up 54.1% year over year, the best in years. But the decomposition is unforgiving. Revenue fell about 19% while the coach base fell about 48%. Divide one by the other and you get roughly the entire productivity gain — mechanically.
The company is doing real work on the quality of that surviving base. The new compensation plan was explicitly redesigned to reward executive-director rank, and Johnson was candid about the trade-off: “we would expect productivity to improve while the quantity of active learning coaches goes down, we are expecting the quality of those coaches to actually improve, and that was a design change in the plan itself.” — Nicholas Johnson, Chief Executive Officer · 2026-10-26 That is coherent. It is also a strategy of managed shrinkage, and shrinkage has a floor: the fourth quarter guide is the first place we can see whether the floor is near.
What management stopped saying
The most revealing signal in this quarter's keyword set is not what rose but what decayed. TRILOGY was a top gainer and comprehensive metabolic health system remains in the language — but on the company's own momentum record, metabolic dysfunction, body composition, metabolic synchronization and "Renew" all fell harder this quarter than they rose in the quarters that made them the whole story. The 14% visceral-fat reduction and 98% lean-mass preservation are still recited, but the emphasis has moved from science to field mechanics: the Trilogy Business Blueprint, the CoachHub, certification standards, the Project Catalyst cost program.
That is a rational pivot. It is also an acknowledgment that four quarters of metabolic-health messaging did not arrest the coach decline. And on GLP 1, the answer has matured into a reframe rather than a rebuttal — GLP-1s as a catalyst for the health journey, with the coach selling the quality of the weight lost. Sensible. Not yet a customer-acquisition engine.
The arithmetic Q4 has to beat
Q4 guidance of $0.00–$0.25 EPS is being sold as the payoff for Catalyst. Run the numbers. Q3 adjusted loss from operations was $4.0 million on $72 million of revenue, with adjusted SG&A of $55.6 million against adjusted gross profit of $51.7 million, at a 69.9% gross margin. Strip roughly $7 million of revenue out at the midpoint of the Q4 guide and you remove about $5 million of gross profit; closing that gap to zero operating income requires something on the order of a further $9 million of adjusted SG&A compression in a single quarter, on top of $13.8 million of Catalyst charges already taken. Interest income of $1.5 million a quarter on the cash pile helps the EPS line, but the guided $2–6 million of adjusted EBITDA excluding interest income is the honest test.
The operating margin is now the whole thesis. So is the valuation: at 0.4x revenue, the market is pricing the brand, the science and the coach network at essentially nothing beyond liquidation. The stock is 96% below its 2021 peak of $332.25, though it has quietly risen 5.5% over the last 90 days and sits about 9% off its August high — a market that has stopped panicking but has not started believing.
The verdict
What changed this quarter is not the strategy; the strategy has been Trilogy-plus-metabolic-health for a year. What changed is the burden of proof. Management has spent four quarters arguing that productivity leads coaches leads revenue. That chain has now been broken for long enough that the company has replaced the argument with a cheaper one: we will be profitable in Q4 on a smaller base. If they hit it, the negative enterprise value becomes absurd and someone notices. If they miss it, the cash pile stops being a floor and starts being a countdown.
Everything hinges on a quarter guided to $65 million at the midpoint — a number that makes "stabilizing" a word Medifast may not use again.